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ABSTRACT 
 
Objectives: To assess associations between the launch of the National Dementia Strategy 
(NDS) and antipsychotic prescribing in long-term residential care (LTC) in England. 
 
Setting and participants: Retrospective analysis of prescribing patterns in 616 LTC institutions 
(31,619 residents) following launch of the NDS, using information from electronic medicines 
management system. 
 
Primary and secondary outcome measures: Antipsychotic prescribing point-prevalence (PP) 
for all residents in a cross-section of LTC settings over a 4-year period following NDS launch.  
Secondary outcomes included: dosages, length of treatment and use of recommended 
second-generation antipsychotics (SGA) versus first-generation antipsychotics (FGA).  
Associations between facility-level PP values and institutional characteristics, resident 
demographics were explored.  Variations across geographical areas examined.  Prescription net 
ingredient costs calculated. 
 
Results: No statistically significant difference was observed in overall prescribing rates over the 
4-year period (Kolmogorov-Smirnov test p=0.60), and there was no significant shift towards 
newer SGAs (KS test p=0.32).  Dosages were above the maximum indicated in only 1.3% of 
cases, but duration of prescribing was excessive in 69.7% of cases.  Care homes in the highest 
prescribing quintile were more likely to be located in a deprived area (Rate Ratio [Q5/Q1] RR = 
5.89, 95% CI 4.35, 7.99), registered for dementia (RR =3.38, 95% CI 3.06, 3.73), and those in 
the lowest quintile were more likely to be served by a single GP practice (RR = 0.48; 95% CI 
0.37, 0.63); p<0.001 all.  A six-fold variation in PP levels was observed between geographical 
areas.  The average annual expenditure on antipsychotics was £65.6 per person resident (2012 
prices). 
 
Conclusions: The NDS in England was not associated with reduced PP levels or the types of 
antipsychotic prescribing in care homes.  Further research is needed to explore why.  Clear 
standards specifying recommended agents, dosages and length of treatment, together with 
routine monitoring and greater accountability for antipsychotic prescribing , may be required. 
 
Strengths and limitations of this study 
1. To our knowledge, this is the first UK study to examine long term impact of a national 
policy initiative on antipsychotic prescribing in care homes. The samples studied are 
many times those of other UK antipsychotic utilisation studies. 
2. Prescribing rates, antipsychotic agent type (including unlicensed antipsychotics), and 
length of treatment were unchanged. 
3. The factors preventing sustained change in antipsychotic prescribing and regional 
variations observed remain unclear. 
4. One limitation of this observational study is the lack of comparable national data to 
demonstrate representativeness of the study sample. 
5. A further limitation of this study is the lack of clinical and staffing data to complement the 
detailed prescription data. 
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INTRODUCTION 
 
There continues to be considerable international debate about the optimum care of older people 
with dementia, especially those living in care homes 1-4.  In England it is estimated that 46% of 
new admissions to care homes are for reasons of dementia 5, and more than one-third of people 
with dementia (36.5%) now live in care homes6.  For antipsychotics, which were originally 
developed for use in patients with schizophrenia or psychosis, there is evidence of ‘off-label’ 
prescribing of unlicensed medicines for behavioural and psychological symptoms in dementia 
(BPSD) 4 7. 
 
In the 1990s, calls in the United States (US) for control of the use of first-generation 
antipsychotics (FGA) for BPSD led to the Omnibus Budget Reconciliation Act (OBRA) which 
introduced regulation stipulating recommended dosages for their use in nursing homes 8 9.  In 
the United Kingdom (UK), thioridazine (trade name Melleril©), a commonly used FGA, was 
banned in 2008 following evidence of cardiac toxicity and limited effectiveness 10.  Prior to its 
ban, thioridazine was the most commonly prescribed antipsychotic in UK long-term residential 
care (LTC), accounting for 51-74% of prescriptions 11 12.  With the introduction of second-
generation antipsychotics (SGA) 13, concerns continued to be raised in the UK and the US about 
their use for BPSD treatment 14 15.  In the US, no antipsychotic has been approved to date by the 
Food and Drug Administration for BPSD 16.  In the UK, the Medicines & Healthcare products 
Regulatory Agency has licensed only one antipsychotic (risperidone), for short-term BPSD 
treatment (up to 6 weeks) and for persistent aggression 17.  Australia and Canada have similarly 
only approved risperidone 18 19.  In most countries therefore use of other antipsychotics 
remains unlicensed or off-label 20.  It has recently been argued that wide-spread off-label 
prescribing for BPSD requires regulatory intervention to safeguard vulnerable older people 21. 
 
Inappropriate prescribing of antipsychotic medication is recognised as a marker of poor care 3 22, 
especially if prescriptions are not regularly reviewed by the prescribing physician 23.  Although 
the principle of protecting older people’s human rights when they cannot consent to treatment is 
well developed with respect to the use of physical restraints and deprivation of liberty, it is 
acknowledged that protection against inappropriate use of ‘chemical restraints’ is less well 
developed 24.  To date, controlled trials have demonstrated limited clinical efficacy for use of 
antipsychotics in BPSD, with only small effect sizes reported on global behavioural 
disturbance 25.  Long term use of antipsychotic drugs is also associated with increasing 
concerns about serious adverse effects including mortality 26.  The European Federation of 
Neurological Societies task force recommended in 2007 that all antipsychotics be used with 
caution in elderly patients with dementia, although no specific guidance was provided on 
dosage or length of treatment 27.   
 
In 2009, the UK Department of Health commissioned a policy review on antipsychotic use in 
dementia.  The resulting report concluded that usage was unacceptably high and recommended 
a two thirds reduction over a period of 3 years as a target 20.  The UK Royal College of 
Psychiatrists confirmed that older people could safely be withdrawn from agents like risperidone 
over a 2–4 week period with no adverse consequences 28 29.  This policy review also stipulated 
that SGA agents should be prescribed in preference to FGA agents; that the lowest possible 
effective dose should be prescribed for the shortest period (ideally less than 12 weeks); and that 
treatment should be reviewed at least monthly with reduction or cessation actively considered at 
each review 20.  Similar recommendations were incorporated as guidelines in a National 
Dementia Strategy (NDS) launched in February 2009, 9 30 31.  
 
In England, the majority of care home residents (60%) are in residential homes typically with no 
on-site nursing staff 32 33.  Although general practitioners (GPs) prescribe and are responsible for 
monitoring medication in care homes, medicines management (ordering, administering) is 
undertaken by social care staff who may have no formal training in medication practice 34.  In the 
US, administration of antipsychotic treatment by untrained staff unaware of safety issues is 
reported to have been a contributory pressure leading to the OBRA initiative. 
 
In this paper, we report the findings of a large scale study in England that examines 
antipsychotic prescribing in nursing and residential homes following the introduction of the NDS.  
To date UK research on medication use in care homes remains limited 35-37, with no large-scale 
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studies of antipsychotic prescribing levels generally or long-term impact of the NDS.  Our 
research investigated whether prescribing levels changed over the 4 years following introduction 
of the NDS guidance; the degree to which recommendations in terms of the types of agents 
prescribed and the length of treatment have been achieved; and variations in the patterns of 
prescribing between different institutions and geographical areas. 
 
OBJECTIVES 
 
 To assess whether the implementation of the National Dementia Strategy was associated 
with a decrease in prescribing of antipsychotics in long-term residential care (LTC) and, 
where prescribed, a shift towards newer SGAs. 
 To examine differences in prescribing patterns between LTC institutions and different 
geographical areas, including the agents prescribed, dosages and length of exposure. 
 To explore the characteristics of high/low prescribing LTC institutions. 
 To consider the potential use of data on prescribing in UK LTC. 
 
METHODS 
 
Overview and Data Preparation 
Prescription data were provided via a double-barcode electronic medicines management (EMM) 
system designed for care homes (see supplementary file 1).  This source had previously been 
used to examine drug administration patterns in care homes 35.  Data were downloaded by the 
company for all care homes with the EMM system for the period 2009 – 2012 downloaded in two 
separate anonymised files and merged for analysis.  The first contained details of all 
antipsychotic prescriptions, and the second de-identified resident data and anonymised LTC 
characteristics.  Data were analysed at two time points: 1st January 2009 (prior to NDS launch) 
and 31st December 2012 (4 years post-NDS).  For each time point, a complete dataset was 
examined to include all residents, there were no exclusions.  Because the number of care 
homes which had implemented the EMM system increased over this period, a data sub-set was 
extracted for a cohort of care homes with the EMM system in place throughout the 4-year period 
(Cohort C).  The National Research Ethics Service, National Patient Safety Agency, London 
W1T 5HD approved this retrospective study, which was designated a service evaluation [Ref: 
04/02 28 October 2009]. 
 
For each prescription, dosage was converted to an equivalent daily dose in mg; administration 
format was classified as tablet, liquid or injection; trade names were re-coded to a common 
single British National Formulary (BNF) name 38.  All non-risperidone use was defined as off-
label.  Care homes were characterised in terms of: type of institution (e.g. nursing, residential 
home); registration status (e.g. registered for ‘dementia’ or ‘old age only’); number of beds; any 
self-declared specialism (e.g. Alzheimer’s care); and geographical location.   
 
Dosages were compared to an ‘indicative’ maximum daily dosage (IDD), pre-defined for each 
agent.  Three different sources were used in turn since there is no comprehensive UK guidance 
on IDD levels for older people.  First, if the BNF contained a recommended dose for ‘agitation 
and restlessness’ in older people or less specifically for ‘elderly patients’ this was used as ‘best 
available’ evidence.  Secondly, if the US OBRA recommendations specified a maximum dosage, 
this was used 8 9.  Finally, for all other agents the upper dosage reported in a UK survey of 
hospital specialists in old age psychiatry for dementia was used 39.  The length of exposure 
(LOE) was estimated by summing repeat antipsychotic prescriptions for each individual 
resident until the final prescription; due to the time consuming nature of this process, such 
analysis was limited to the licensed agent (risperidone). 
 
Measurements 
We calculated the following: 
 Prescribing levels in terms of point-prevalence (PP) i.e. the percentage of residents 
prescribed at least one antipsychotic at each time point. 
 For each prescription, the observed daily dosage classified in terms of ‘indicative’ maximum 
daily dosage (IDD) for that agent.  Dosage was categorised as ‘recommended’ (≤IDD), ‘high’ 
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(>100% - 200% IDD) or ‘excessive’ (>200% IDD).  Cases of pro re nata (PRN) or “as 
needed” prescribing were recorded separately. 
 LOE values were compared to the recommended 6 weeks 17 and 12 week maximum  20 30.  
LOE was categorised as ‘recommended’ (≤6 weeks treatment), ‘acceptable’ (>6 to <12 
weeks) or ‘excessive’ (≥12 weeks). 
 Net ingredient cost of each antipsychotic prescription, excluding any dispensing costs or 
fees, was estimated using BNF unit prices (accessed 6th December 2012). 
 Primary medical support was categorised in terms of the number of GP practices serving an 
LTC facility plus the size of these practices (i.e. number of doctors).  An additional proxy 
measure of quality was whether these included a teaching practice. 
 LTC neighbourhoods were classified as ‘deprived’ or ‘non-deprived’, with deprived defined 
as a neighbourhood in the top 10 per cent of Index of Multiple Deprivation scores nationally 
40. 
 Each LTC was linked to the body responsible for health services in its geographical area (i.e. 
Primary Care Trusts (PCTs) at this time); PCTs were coterminous with local government 
authorities responsible for provision of LTC social care services 41. 
 
Statistical Analysis 
A comparative descriptive design was adopted comparing cross-sectional and longitudinal data.  
Numerical data were summarised using mean and SD or median and range depending on data 
distribution. Stata (version 12) was used for all analyses. 
 
Sample descriptors and prescribing patterns 
Prescribing patterns were analysed to include PP levels for all antipsychotics and for FGAs / 
SGAs separately, dosages in terms of IDD levels, and LOE for risperidone.  The mean annual 
expenditure on antipsychotics per resident was estimated by summing the cost of all 
prescriptions in an LTC setting and dividing by the total number of residents; costs were 
adjusted to 2012 prices 42. 
 
Trend in prescribing  
Cumulative distribution plots of PP values were produced for all antipsychotics, and separately 
for FGA and SGA agents.  The 2-sample Kolmogorov-Smirnov nonparametric statistical test 
(ks2-test) was used to compare distributions at baseline and 48 months 43.  Plots for the common 
sub-set (Cohort C) were similarly compared. 
 
Characteristics of high/low prescribing institutions 
Care homes were placed into quintiles based on their baseline PP level; if an organisation was 
placed in a particular quintile, all residents in that home were placed in the same quintile.  
Quintiles were compared for categorical variables (i.e. resident demographics and care home 
characteristics).  Rate ratios were derived for the fifth quintile divided by the first quintile and 
95% confidence interval limits reported using a delta-method standard error.  
 
Geographical variations 
For each PCT area, the mean prescribing level (PP value across all care homes), ratio of 
SGA:FGA prescriptions, and the proportion of off-label (i.e. non-risperidone) prescriptions were 
estimated.  For risperidone, the proportion of cases in which this was the first-line therapy was 
calculated, together with PP values for risperidone. 
 
RESULTS 
 
Sample descriptors 
Table 1 shows details of baseline and 48 month samples. The mean age of residents was 83.7 
years (baseline) and 78.8 years (48 months) and the majority were female (71.9% vs 68.0%).  
Cohort C demonstrated a similar age/gender breakdown.  At baseline, 55% of care homes 
operated in a ‘multi-practice’ context (served by ≥4 GP practices), with only 13.7% served by a 
single GP practice; 24% had access to at least one teaching GP practice.  Number of GP 
practices was not related to care home size, so in the multi-practice model individual GP 
practices were caring for 3 - 13 residents versus 30 - 41 patients in the single practice model.  
48% of care homes were registered for dementia and the remainder for ‘old age only’. 
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Table 1  - Care Home and Resident Characteristics 
 
 
Sample characteristics 
Total Cohort C  
Baseline 
(1 Jan 2009) 
Month 48 
(31 Dec 2012) 
Baseline 
(1 Jan 2009) 
Month 48 
(31 Dec 2012) 
Number of homes 211 616 166 166 
Number of residents 8,357 31,619 6,979 9,006 
Resident Demographics     
Women, % 71.9 68.0 71.9 69.1 
Age years (mean) 83.7 78.8 83.8 80.1 
65–74 years, % 8.9 16.9 8.8 14.4 
75–84 years, % 34.8 44.5 34.8 45.5 
85 years and over, % 52.5 30.3 52.8 34.0 
Care Home Characteristics     
Mean size (number of residents) 39.6 51.3 42.0 54.3 
Median size [IQ range] 37 [18] 46 [30] 39 [19] 49 [28] 
Type of home (% all homes)     
Residential home, % 47.9 25.8 48.8 48.2 
Nursing home, % 39.3 23.5 39.2 34.9 
Dual registered* , % 12.8 50.7 12.1 16.9 
Medical support (% all homes)     
1 GP practice, % 13.7 11.0 11.5 8.4 
2-3 GP practices, % 31.3 29.7 31.9 29.5 
4+ GP practices 55.0 59.3 56.6 62.1 
 
* Providing both nursing and residential care. 
 
 7 
 
Pattern of antipsychotic agents prescribed 
Table 2 provides a detailed breakdown of antipsychotic prescribing over the 48 month period.  
This shows that mean PP rates did not reduce significantly; 18% at baseline vs. 19% at 48 
months post-NDS.  Further analysis indicates that nursing and residential homes exhibit similar 
PP rates; 17.3% and 18.6% respectively at baseline, and 21.0% and 19.2% at 48 months.  
SGAs are the most frequently used agents (68% of all prescriptions), as recommended in the 
NDS, with no significant differences between nursing and residential homes.  Similar patterns 
are observed in Cohort C.  FGA agents are prescribed less often than SGAs, with haloperidol 
the most commonly used.  Although 6 residents were still prescribed the banned FGA 
thioridazine at baseline, by 2012 this figure had fallen to zero. 
 
Residents were very rarely (0.7% at baseline and 1.67% at 48 months) prescribed more than 
one antipsychotic at the same time.  Most antipsychotics were administered in tablet form (82%) 
with 17% as an oral liquid.  The average annual expenditure on antipsychotics was £65.6 per 
person resident (2012 prices).  Expenditure was slightly higher in nursing homes (£71.0) than 
residential homes (£60.4). 
 
The vast majority of treatments at baseline (82%) were above the recommended 6 weeks; at the 
end of 2012 this figure had risen to 87.3%, with 69.7% and 77.6% respectively above 12 weeks.  
In contrast, dosages were within IDD levels in 98.7% of cases at baseline; PRN prescriptions 
were extremely rare (<1%). 
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Table 2  - Breakdown of Antipsychotic Prescribing Patterns 
 
 
Prescribing 
Total Cohort C  
Baseline 
(1 Jan 2009) 
Month 48 
(31 Dec 2012) 
Baseline 
(1 Jan 2009) 
Month 48 
(31 Dec 2012) 
Point-prevalence (PP), %     
All Antipsychotics     
Mean (standard deviation) 18.0 (±12.0) 19.0 (±15.2) 18.3 (±11.9) 18.0 (±12.3) 
Median [Inter-quartile range] 15.2 [11.8] 15.4 [14.0] 15.3 [11.4] 15.1 [12.7] 
Second-Generation Agents (SGAs)     
All Second-Generation Agents 12.5 14.6 12.8 13.9 
    Quetiapine 5.1 4.7 4.9 3.9 
    Risperidone 4.0 5.3 4.2 6.4 
    Olanzapine 2.1 3.0 2.3 2.9 
First-Generation Agents (FGAs)     
All First-Generation Agents 5.9 5.4 5.8 5.2 
    Halperidol 2.5 3.0 2.3 2.4 
Daily dosage, %*     
Recommended  98.7 NA 98.6 NA 
High 0.3 NA 0.3 NA 
Excessive 1.0 NA 1.1 NA 
Length of exposure, %**      
Recommended 18.0 12.8 18.2 10.2 
Acceptable 12.3 9.7 12.2 6.4 
Excessive 69.7 77.6 69.7 83.5 
 
* Percentage of total prescriptions with following daily dosage: ‘Recommended’ = ≤ Maximum IDD; ‘High’ = >100% to 200% IDD; ‘Excessive’ = >200% IDD. 
** Percentage of risperidone prescriptions with following LOE: ‘Recommended’ ≤6 weeks; ‘Acceptable’ >6 to <12 weeks; ‘Excessive’ ≥12 weeks. 
NA, not applicable  
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Trends in prescribing 
Figure 1 displays cumulative distribution PP plots at baseline and 48 months post-NDS for all 
care homes (Figure a) and separately for Cohort C (Figure b).  No statistically significant 
decreases were observed for either (Kolmogorov-Smirnov test p=0.60 and p=0.74 respectively).  
For SGAs and FGAs separately, a similar analysis indicates no significant shift towards newer 
SGAs (KS test p=0.32) or away from FGAs (KS test p=0.26). 
 
Characteristics of high/low prescribing institutions 
Table 3 presents the characteristics of residents and LTC institutions in the highest and lowest 
prescribing quintiles.  In terms of care home characteristics, size and type of institution (nursing 
or residential) show no clear differences.  However, the highest quintile is more likely to include 
residents in institutions situated in a deprived neighbourhood (Rate Ratio [Q5/Q1] RR = 5.89, 
95% confidence interval [CI] 4.35, 7.99), those in homes registered for dementia (RR = 3.38, 
95% CI 3.06, 3.73), or residents in homes served by 4 or more GP practices (RR = 1.38; 95% CI 
1.30, 1.46).  In terms of resident characteristics, older residents aged 85 years plus were less 
likely to be in the upper quintile (RR = 0.63, 95% CI 0.58, 0.68) and younger residents aged 65-
74 more likely (RR = 1.75, 95% CI 1.41, 2.17).  75-84 year olds have a 95% CI in which does 
not overlap with the other two groups suggesting they are more likely to be in the upper quintile 
than those aged 85+ but less likely than those aged 65-74.  There was a slight gender difference 
(females RR = 0.86, 95% CI 0.82, 0.90). 
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Table 3 - Care homes and residents in high and low prescribing quintiles 
(Baseline sample) 
 
  Quintile  
Rate Ratio (RR, 
95% CI) 
 
Q5/Q1 
 Total population Q1 (Lowest) Q5 (Highest) 
CARE HOME CHARACTERISTICS 
Home Type     
Residential home – No. (%) 3703 (44.3) 831 (46.3) 737 (51.5) 1.11 (1.04, 1.19) 
Nursing home – No. (%) 3422 (41.0) 682 (38.0) 561 (39.2) 1.03 (0.95, 1.13) 
Dual registered – No. (%) 1232 (14.7) 282 (15.7) 133 (9.3) 0.59 (0.49, 0.72) 
All    P<0.001 
Registered for dementia 3359 (48.0) 335 (22.3) 913 (75.4) 3.38 (3.06, 3.73) 
Registered for old age, not dementia 3644 (52.0) 1168 (77.7) 298 (24.6) 0.32 (0.29, 0.35) 
    P<0.001 
Area Deprivation     
Deprived neighbourhood – No. (%) 459 (6.1) 48 (2.9) 219 (17.1) 5.89 (4.35, 7.99) 
Non-deprived neighbourhood – No. 
(%) 
7089 (93.9) 1598 (97.1) 1059 (82.9) 0.85 (0.83, 0.88) 
All    P<0.001 
Practices serving home     
1 GP practice – No. (%) 866 (10.4) 180 (10.0) 68(4.8) 0.48 (0.37, 0.63) 
2-3 GP practices – No. (%) 3011 (36.0) 729 (40.6) 387(27.0) 0.67 (0.60, 0.74) 
4+ GP practices – No. (%) 4480 (53.6) 886 (49.4) 976 (68.2) 1.38 (1.30, 1.46) 
All    P<0.001 
Care Home Size*      
Small – No. (%) 545 (6.5) 183 (10.2) 95 (6.6) 0.65 (0.51, 0.82) 
Medium – No. (%) 2887 (34.6) 554 (30.9) 643(44.9) 1.45 (1.33, 1.59) 
Large – No. (%) 4925 (58.9) 1058 (58.9) 693(48.5) 0.82 (0.77, 0.88) 
All    P<0.001 
Age/Gender of Residents 
Women – No. (%) 
8,357 
6,011 (71.8) 
1,795 
1,343 (74.8) 
1,431 
922 (64.4) 
 
0.86 (0.82, 0.90) 
Age 65-74 – No. (%) 744 (8.9) 129 (7.2) 181 (12.6) 1.75 (1.41, 2.17) 
Age 75-84– No. (%) 2,911 (34.8) 554 (30.9) 564 (39.4) 1.28 (1.16, 1.40) 
Age 85+ – No. (%) 4,392 (52.5) 1,071 (59.7) 536 (37.5) 0.63 (0.58, 0.68) 
All    P<0.001 
Abbreviations: NA, not applicable. 
*   Small = ≤ 24 residents; Medium = 25-39 residents; Large ≥40 residents. 
CI: confidence interval. 
P values in the Rate Ratio column are from Pearson’s chi-squared test of associated between the 
characteristic variable and the first and fifth quintile indicator. 
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Geographical variations 
Table 4 presents PCT-level data for the 26 geographical areas in which care homes are located.  
PCT areas, arranged in order of decreasing PP rate, demonstrate a six-fold variation in 
prescribing level between 5.7% and 37.5% (overall mean 17.6%).  The proportion of 
prescriptions for SGAs similarly shows an eight-fold difference, ranging between 11.1% and 
89.5% (mean 62.9%), with SGA use unrelated to overall PP value.  Rates of off-label (non-
risperidone) prescribing vary between 5.4% and 31.3% (mean 13.9%).  For risperidone, an 
overall PP value of 3.7% masks large geographical differences (range 0% to 6.2%).  Detailed 
analysis of risperidone prescriptions also indicates that, although this was the first-line treatment 
in 75.2% of cases when prescribed, this figure varies between 0% and 100% in individual PCTs 
as shown in the final column. 
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Table 4  - Prescribing Patterns by Geographical Area (Baseline sample) 
 
PRIMARY CARE 
TRUST (PCT) AREA 
 
 
PRESCRIBING PATTERNS 
Antipsychotic prescriptions 
 
Risperidone  
prescriptions 
 
 
Point-
prevalence 
All 
(%) 
 
Proportion 
SGA 
agents 
(%) 
 
 
Point-
prevalence  
off-label 
prescribing 
(%) 
 
 
Point-
prevalence 
(%) 
 
Percentage 
which are 
first-line 
prescriptions 
(%) 
AREA 1 37.5 11.1 31.3 6.2 0 
AREA 2 24.8 49.4 22.7 2.1 83.3 
AREA 3 24.3 33.3 21.6 2.7 100.0 
AREA 4 24.1 89.4 20.0 4.1 81.8 
AREA 5 23.5 67.8 21.0 2.5 90.0 
AREA 6 22.0 66.7 16.0 6.0 100.0 
AREA 7 20.9 60.6 19.2 1.7 87.5 
AREA 8 20.6 37.7 18.2 2.4 83.3 
AREA 9 19.9 70.0 13.8 6.1 78.8 
AREA 10 19.2 19.0 18.7 0.5 100.0 
AREA 11 17.6 60.5 12.4 5.2 63.2 
AREA 12 17.5 54.5 17.5 0 NA 
AREA 13 17.3 78.6 15.9 1.4 100.0 
AREA 14 17.0 39.4 13.4 3.6 57.7 
AREA 15 15.6 68.2 13.4 2.2 50.0 
AREA 16 15.5 76.9 14.5 1.0 100.0 
AREA 17 15.1 75.7 10.2 4.9 81.2 
AREA 18 15.1 60.0 15.1 0 NA 
AREA 19 14.3 89.5 13.4 0.9 0 
AREA 201 14.1 74.1 13.4 0.7 100.0 
AREA 21 13.4 69.4 11.3 2.1 100.0 
AREA 22 13.2 25.0 10.6 2.6 0 
AREA 23 11.8 29.6 10.5 1.3 0 
AREA 24 10.8 85.7 5.4 5.4 100.0 
AREA 25 8.7 80.0 7.5 1.2 100.0 
AREA 26 5.7 66.7 5.7 0 NA 
Total 17.6 62.9 13.9 3.7 75.2 
 
NA, not applicable  
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DISCUSSION 
 
This study has used data on many more care home residents than any similar UK study.  This 
shows that reductions in the prescribing of antipsychotics driven by the National Dementia 
Strategy have not been sustained in care homes.  Furthermore, we demonstrate that contrary to 
guidance older antipsychotic agents are still being used extensively rather than safer, second-
generation antipsychotics.  We observed that most residents were prescribed antipsychotics 
within acceptable dosages however, in the majority of cases, length of treatment was 
excessive.  These results differ from an analysis of UK GP practice records over 16 years which 
identified a fall in levels of prescribing of antipsychotics at the point when dementia is first 
recorded, from 19.9% in 1995 to 7.4% in 2011 44.  A recent study in England found that the 
launch of the NDS was linked to an increase in diagnosis rates and prescriptions for anti-
dementia medications from 2006/2007 to 2011/2012 45.  A trend towards earlier diagnosis may 
explain the fall in antipsychotic prescribing reported in 2011 in the first study 44.  Neither study 
provided separate figures for care homes. In the US, differences in prescribing rates in nursing 
homes before and after the introduction of OBRA have been reported 46. 
 
English studies of antipsychotic prescribing levels in care homes are limited, usually based on 
small samples (<1,000 people) typically undertaken in a single geographical area 20.  Even so, 
similar rates to those found in our study have been reported; 17.8% for residential and 21.9% 
for nursing homes in a single-region study 47, 20% for a single-city study in 65 care homes 4, and 
24.5% in a single-region study among 934 residents 12.  Elsewhere, it has been suggested that 
up to 27% of UK care home residents may be receiving antipsychotics 48.  More recently, a 
survey of care home managers in the East of England identified a rate of 12%; although this was 
self-reported by 299/737 managers so response bias cannot be ruled out 49.  Internationally, US 
rates appear to be slightly higher, although studies are limited to nursing homes 50.  Rates of 
27.6% in 2000-2001 3, 28% in 2005 3, and 25% in 2011 51 have been reported for large scale 
population samples.  In contrast to these US figures, which are based on 2-3 million Medicare 
beneficiaries, smaller scale studies in other parts of the world generally report higher levels of 
antipsychotic use 46.  Reported rates in 2005-2006 include 30.3% and 36.9% in two Canadian 
LTC facilities 52, 25.1% in 40 Australian nursing homes 18, and 39%-42% in 41 institutions in 
Finland 53.  The rates observed in our study are therefore comparatively low. 
 
Although we found no decrease in overall prescribing levels, it is also important to consider why 
we observed no shift towards SGAs, why off-label prescribing remained high, and why length of 
treatment continued to exceed the recommended 6-12 weeks (although dosages were within an 
acceptable range).  A comparable 2005 analysis of data for US nursing home residents found 
73.5% were receiving SGAs, 13.4% FGAs and 13.04% both 3.  In our study, the proportion of 
SGAs was similar at 69%, but <2% residents were prescribed more than one agent.  In 
Australia, a much lower level (40%) of SGA use has been reported in a cohort study of 2,005 
residents 54.  In our baseline cohort, the most commonly prescribed SGAs were quetiapine, 
risperidone and olanzapine.  This is similar to self-reported preferences in a survey of UK 
hospital specialists in old age psychiatry 39.  In terms of dosage levels, there is no other recent 
UK evidence available.  However, a US study found that 17.2% of 1,096 nursing home 
residents were prescribed antipsychotic doses (excluding PRN) that exceeded maximum levels 
3.  Our study indicates a lower level of 1.3% in England.  Our findings also confirm that off-label 
prescribing continues to be a problem.  In March 2012, the US Centers for Medicare and 
Medicaid Services launched a quality initiative that recommended a 15% decrease in off-label 
prescribing of unlicensed antipsychotics in nursing homes over nine months 55.  No similar 
quality initiative has been launched in the UK. 
 
The key drivers influencing excessive treatment length are unclear.  No data are published on 
who initiates antipsychotic treatment in LTC in England (e.g. hospital clinicians or GPs), 
although there is research on continuation of treatment.  A study in one UK region found 
that 79% of residents in 10 care homes who were prescribed risperidone or olanzapine were 
under GP-only care, and monitored only infrequently 13.  Similarly, a study of 65 English care 
homes identified infrequent monitoring with only 25% of residents who were prescribed an 
antipsychotic receiving a medication review by their GP in the preceding 12 months 4.  More 
recently, a British Geriatrics Society Inquiry found that continuation of therapy is largely 
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managed by GPs, with evidence that they may fail to undertake regular reviews as 
recommended 56.  The excessive treatment length observed in our cohort may therefore be 
associated with a lack of regular review by GPs or community pharmacists.  An added reason 
offered for continuation of antipsychotic treatment in care homes is to reduce distress of staff 57 
58.  Against this, there is evidence of wide variability in distress amongst care staff exposed to 
the same resident behaviour, and poor agreement amongst senior staff about which of their 
residents present with challenging behaviour 59.  In fact, research from Denmark indicates that 
behavioural problems are a determinant for the use of antipsychotics, irrespective of the 
resident’s diagnosis 60. 
 
The large variations we observed in antipsychotic use between care homes may be due to 
various factors such as clinical need, staffing levels or broader organisational factors such as 
leadership and investment in staff development61.  Although we found residents in care homes 
registered for dementia were over-represented in our highest prescribing quintile indicating a link 
with clinical need, other factors appeared to have a greater impact.  Since we lacked clinical 
data to complement the detailed prescription data, this could not be explored further.  However, 
researchers elsewhere have identified that clinical need does not appear to be a key driver 
influencing prescribing rates.  A Canadian study which recorded a three-fold variation among 
485 nursing homes found that residents were prescribed antipsychotics irrespective of clinical 
indication 62.  Similarly, for 16,586 newly admitted nursing home residents, a US study reported 
that someone entering a home which exhibits the highest prescribing rate is 1.37 times more 
likely to receive antipsychotics, after adjusting for potential clinical indications, than someone 
admitted to the lowest prescribing facilities 2. 
 
‘Prescribing culture’ has therefore been suggested as an important factor influencing 
antipsychotic use in nursing home 2 63-66.  In our study, although we could not measure 
prescribing culture, residents in homes served by a single GP practice were more likely to be in 
the lowest prescribing quintile, compared to LTC settings with more complex multi-practice 
medical support.  Treatment culture may be influenced by a more consistent message provided 
by one practice, with requests to continue use of antipsychotics addressed more appropriately.  
In the multi-practice context, where up to 21 GP practices served a single care home, the lack of 
consistent messages may emerge, especially important in residential homes where medication 
is managed by non-clinical social care staff who may require more consistent advice and support 
34. 
 
Interestingly, our findings also indicate that residents in care homes located in deprived 
neighbourhoods are significantly over-represented in the highest prescribing quintile.  Although 
there is no other similar UK research, a US study of 17,000 care homes has identified that, 
compared to ‘not-for-profit’ or government-owned homes, residents in ‘for-profit’ nursing homes 
are more likely to be prescribed antipsychotics; this finding was explained by lower nurse staffing 
levels 67.  Evidence on a direct relationship between staffing levels and antipsychotic use is 
currently lacking 68.  However, a measurable and sustained reduction in nursing staff burden has 
been reported in a double-blind, placebo-controlled randomised controlled trial (RCT) of 
risperidone treatment in 279 older nursing home residents with dementia 69.  A more recent RCT 
has found that medication also reduces informal carer time by half, but is not cost-effective 
compared with placebo when examining the primary clinical outcome of change in depressive 
symptoms 70.  Although we did not have staffing details in our study, six homes in the sample 
were identified by the Care Quality Commission (CQC) as having inadequate staffing levels 71, 
and all were located in deprived neighbourhoods.  Placing this in context, the mean annual 
expenditure on antipsychotics we observed was £65.60 per resident.  This is <1% of the annual 
cost of a UK residential home place for a person with dementia (£32,241 72).  
 
Finally, very few studies have examined geographical variations in prescribing in LTC.  A recent 
survey of US nursing homes identified a three-fold geographical difference, with lower 
antipsychotic prescribing levels in Hawaii (12.4%) than in Louisiana (33.5%); this was based on 
self-reported rates so response bias cannot be excluded 51.  Our study identified even larger 
geographical differences in off-label prescribing, and similar variations in whether the licensed 
agent was prescribed as first-line therapy.  There is no evident reason for this. 
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The current study presents data from a larger sample of care homes than other UK studies to 
date, but there are a number of limitations.  Firstly, a lack of data on care home characteristics at 
a national-level means that it is not possible to demonstrate representativeness of the sample.  
Because these care homes were early adopters of the EMM innovation, it could be argued that 
they might also be high performers in terms of resident care, leaving little room for improvement 
in antipsychotic prescribing levels.  However, the large range we observed in antipsychotic use 
between care homes, and in the types of antipsychotics prescribed and lengths of treatment, 
would seem to contradict this hypothesis.  A further limitation was the absence of electronic 
health records in the facilities studied, to complement the comprehensive electronic prescription 
data and identify all residents with a diagnosis of dementia.  However, the majority of people 
with dementia in the UK did not have a formal diagnosis during this period 20, so it would have 
been difficult to identify such residents confidently using routine data 17.  The UK is not unusual, 
and barriers to the introduction of electronic health records in long-term care facilities are 
recognised internationally 73.  Finally, although there is a possibility that the NDS may have had an 
impact on antipsychotic use in care homes at the time of its launch with central support, our data clearly 
indicates that this was not sustained over time.  
 
Policy and research implications 
The National Dementia Strategy was not associated with sustained change in the use of 
antipsychotics in people resident in care homes. The economic burden of dementia in the UK is 
estimated to be £4 billion per year, more than cancer, heart disease and stroke combined 74.  
Further strategies may be required to achieve control and reduce the inappropriate use of 
antipsychotics in care homes 75.  As a first step, standards specifying recommended agents, 
dosages and length of treatment would be helpful.  Secondly, consideration should be given to 
routine reporting of patterns of prescribing for care home residents that are subject to 
regulatory scrutiny; the National Dementia Strategy did not include long term monitoring 
mechanisms let alone enforcement mechanisms.  Antipsychotic prescribing patterns in UK care 
homes are not open to public scrutiny nor routinely reported by regulatory inspection.  Finally, 
research is needed to explore why prescribing appears to have been unaffected by the NDS. 
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